Litigation Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2018)
✉ Email this page to a colleague
AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2018)
| Docket | ⤷ Sign Up | Date Filed | 2018-10-12 |
| Court | District Court, N.D. West Virginia | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Irene Patricia Murphy Keeley |
| Jury Demand | None | Referred To | Robert W. Trumble |
| Patents | 10,166,247; 7,759,328; 7,967,011; 8,143,239; 8,575,137 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in AstraZeneca AB v. Mylan Pharmaceuticals Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2021-03-01 | 431 | Memorandum & Opinion | infringement claims for U.S. Patent No. 10,166,247 (the “’247 patent”) (Dkt. No. 89), and deleted…States Patent No. 8,143,239 (“the ’239 Patent”); and claims 10 and 19 of United States Patent No. 8,575,137…History of Patents-In-Suit The Patent and Trademark Office (“PTO”) issued the patents-in- suit…, 13, and 14 of United States Patent No. 7,759,328 (“the ’328 Patent”); claims 12, 13, 18, and 19 …8,575,137 (“the ’137 Patent”) (collectively, “the asserted claims” or the “patents-in-suit”) are | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
